What question did this study set out to answer?

Evaluate the health-related quality of life and work-related outcomes in individuals with obesity treated with tirzepatide or other obesity medications.

April 14, 2026Advances in Therapy0 citationsOpen Access

Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™

TGTheresa Hunter Gibble ALAndrea LeithAdelphi Group (United Kingdom)LHLewis HarrisonAdelphi Group (United Kingdom)

Key Points

Evaluate the health-related quality of life and work-related outcomes in individuals with obesity treated with tirzepatide or other obesity medications.
Exploratory real-world study conducted in the United States
Comparison of health-related quality of life between individuals on tirzepatide and those not on treatment
Assessment of work-related outcomes between individuals on tirzepatide or alternative obesity medications and those not on treatment.
Individuals on tirzepatide reported less impairment in SF-36v2 domains compared to those not on tirzepatide
Individuals on tirzepatide or other obesity medications showed lower impairment in work-related outcomes than those not on treatment.

Abstract

This real-world exploratory study in the US suggests that PwO taking tirzepatide reported less impairment in some of the SF-36v2 domains than those not on tirzepatide. PwO on tirzepatide or alternative OMM treatment appeared to have numerically lower impairment in work-related outcomes than those not on treatment. These findings warrant evaluation for long-term impact of tirzepatide and OMMs on work-related and HRQoL outcomes among PwO.

AI से पूछें

Bookmark

View Full Paper